Synthesis and biological evaluation of 5-(alkyn-1-yl)-1-(p-toluenesulfonyl) uracil derivatives

Canadian Journal of Chemistry

Volumn 84, Issue 4, 2006, Pages 580-586

  Janeba, Zlatko ^a,c   Balzarini, Jan ^b   Andrei, Graciela ^b   Snoeck, Robert ^b   De Clercq, Erik ^b   Robins, Morris J ^a  

^a N243 Eyring Science Center   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c Moravek Biochemicals Inc   (United States)

Author keywords

1 (p toluenesulfonyl)pyrimidine derivatives; Antiviral screening, furo 2,3 d pyrimidin 2(3H) one derivatives; Sonogashira coupling

Indexed keywords

CYTOLOGY; DERIVATIVES; SYNTHESIS (CHEMICAL); TOXICITY; VIRUSES;

1-(P-TOLUENESULFONYL)PYRIMIDINE DERIVATIVES; ANTIVIRAL SCREENING, FURO[2,3-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES; HUMAN CYTOMEGALOVIRUS (HCMV); SONOGASHIRA COUPLING;

AMINES;

5 (ALKYN 1 YL) 1 (4 TOLUENESULFONYL)URACIL DERIVATIVE; 5 (ALKYN 1 YL)URACIL DERIVATIVE; 5 (DECYN 1 YL) 1 TOSYLURACIL; 5 (DECYN 1 YL)URACIL; 5 (DODECYN 1 YL) 1 TOSYLURACIL; 5 (DODECYN 1 YL)URACIL; 5 (HEPTYN 1 YL) 1 TOSYLURACIL; 5 (HEPTYN 1)URACIL; 5 (HEXYN 1 YL) 1 TOSYLURACIL; 5 (HEXYN 1 YL)URACIL; 5 (NONYN 1 YL) 1 TOSYLURACIL; 5 (NONYN 1 YL)URACIL; 5 (OCTYN 1 YL) 1 TOSYLURACIL; 5 (OCTYN 1 YL)URACIL; 5 (TRIMETHYLSILYLETHYNYL)URACIL; 5 ETHYNYL 1 TOSYLURACIL; 5 ETHYNYLURACIL; 5 IODO 1 TOSYLURACIL; FURO[2,3 D]PYRIMIDIN 2(3H) ONE; IODOURACIL; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CATALYSIS; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MOUSE; NONHUMAN; SONOGASHIRA REACTION; VARICELLA ZOSTER VIRUS;

EID: 33745909931     PISSN: 00084042     EISSN: None     Source Type: Journal    
DOI: 10.1139/V06-041     Document Type: Article

References (18)

1. M.J. Robins and P.J. Barr. Tetrahedron Lett. 22, 421 (1981).
2. M.J. Robins and P.J. Barr. J. Org. Chem. 48, 1854 (1983).
3. C. McGuigan, C.J. Yarnold, G. Jones, S. Velázquez, H. Barucki, A. Brancale, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini. J. Med. Chem. 42, 4479 (1999).
4. C. McGuigan, A. Brancale, H. Barucki, S. Srinivasan, G. Jones, R. Pathirana, S. Blewett, R. Alvarez, C.J. Yarnold, A. Carangio, S. Velázquez, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini. Drugs Fut. 25, 1151 (2000).
5. J. Balzarini and C. McGuigan. J. Antimicrob. Chemother. 50, 5 (2002).
6. E. De Clercq. Med. Res. Rev. 23, 253 (2003).
7. (a) K. Miranda. M.S. thesis, Brigham Young University, Provo, Utah. 2001;
8. (b) M.J. Robins, K. Miranda, V.K. Rajwanshi, M.A. Peterson, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini. J. Med. Chem. 49, 391 (2006).
9. C. McGuigan, R.N. Pathirana, R. Snoeck, G. Andrei, E. De Clercq, and J. Balzarini. J. Med. Chem. 47, 1847 (2004).
10. Z. Janeba, J. Balzarini, G. Andrei, R. Snoeck, E. De Clercq, and M.J. Robins. J. Med. Chem. 48, 4690 (2005).
11. R.C. Bleackley, A.S. Jones, and R.T. Walker. Tetrahedron, 32, 2795 (1976).
12. K. Eger, M. Jalalian, and M. Schmidt. J. Heterocycl. Chem. 32, 211 (1995).
13. B. Kasnar, I. Krizmanic, and M. Zinic. Nucleosides Nucleotides, 16, 1067 (1997).
14. E. De Clercq, J. Descamps, J. Balzarini, J. Giziewicz, P.J. Barr, and M.J Robins. J. Med. Chem. 26, 661 (1983), and refs. cited therein.
15. J.-I. Asakura and M.J. Robins. J. Org. Chem. 55, 4928 (1990).
16. J.W.B. Cooke, R. Bright, M.J. Coleman, and K.P. Jenkins. Org. Process Res. Dev. 5, 383 (2001).
17. J. Balzarini, R. Sienaert, S. Liekens, A. Van Kuilenburg, A. Carangio, R. Esnouf, E. De Clercq, and C. McGuigan. Mol. Pharmacol. 61, 1140 (2002).
18. T.B. Johnson and C.O. Johns. J. Biol. Chem. 1, 305 (1906).